 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | JNJ-64417184 / J&J
Journal: JNJ-7184, a Respiratory Syncytial Virus inhibitor targeting the connector domain of the viral polymerase. (Pubmed Central) - Jun 17, 2024
JNJ-7184 prevented RSV replication and transcription by inhibiting initiation or early elongation. JNJ-7184 was effective in air-liquid interface cultures and therapeutically in neonatal lambs, acting to drastically reverse the appearance of lung pathology.
- JNJ-64417184 / J&J
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: A Study to Evaluate the Effect of Renal Impairment on JNJ-64417184 and Its Two Minor Metabolites JNJ-68294291 and JNJ-65201526 in Adult Participants (clinicaltrials.gov) - Jan 14, 2021
P1, N=6, Terminated, Sponsor: Janssen Pharmaceutica N.V., Belgium
JNJ-7184 was effective in air-liquid interface cultures and therapeutically in neonatal lambs, acting to drastically reverse the appearance of lung pathology. N=36 --> 6 | Trial completion date: Jul 2021 --> Nov 2020 | Recruiting --> Terminated | Trial primary completion date: Jun 2021 --> Nov 2020; company decision
- | JNJ-64417184 / J&J
Trial completion: A Study to Assess the Effects of Acid-Reducing Agent(s) on JNJ-64417184 in Healthy Participants (clinicaltrials.gov) - Nov 17, 2020
P1, N=14, Completed, Sponsor: Janssen Research & Development, LLC
N=36 --> 6 | Trial completion date: Jul 2021 --> Nov 2020 | Recruiting --> Terminated | Trial primary completion date: Jun 2021 --> Nov 2020; company decision Recruiting --> Completed
- | JNJ-64417184 / J&J
Trial completion: A Study of JNJ-64417184, Administered as an Oral Solution, in Healthy Participants (clinicaltrials.gov) - Sep 1, 2020
P1, N=16, Completed, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed Recruiting --> Completed
- | JNJ-64417184 / J&J
Enrollment open: A Study to Assess the Effects of Acid-Reducing Agent(s) on JNJ-64417184 in Healthy Participants (clinicaltrials.gov) - Aug 23, 2020
P1, N=14, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed Not yet recruiting --> Recruiting
- || JNJ-64417184 / J&J
Enrollment open: A Study to Evaluate the Effect of Renal Impairment on JNJ-64417184 and Its Two Minor Metabolites JNJ-68294291 and JNJ-65201526 in Adult Participants (clinicaltrials.gov) - Jul 26, 2020
P1, N=36, Recruiting, Sponsor: Janssen Pharmaceutica N.V., Belgium
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | JNJ-64417184 / J&J
Enrollment change: A Study of JNJ-64417184, Administered as an Oral Solution, in Healthy Participants (clinicaltrials.gov) - Jul 7, 2020
P1, N=16, Recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting N=32 --> 16
- | JNJ-64417184 / J&J
New P1 trial: A Study to Assess the Effects of Acid-Reducing Agent(s) on JNJ-64417184 in Healthy Participants (clinicaltrials.gov) - Jun 30, 2020
P1, N=14, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- || JNJ-64417184 / J&J
New P1 trial: A Study to Evaluate the Effect of Renal Impairment on JNJ-64417184 and Its Two Minor Metabolites JNJ-68294291 and JNJ-65201526 in Adult Participants (clinicaltrials.gov) - Jun 11, 2020
P1, N=36, Not yet recruiting, Sponsor: Janssen Pharmaceutica N.V., Belgium
- | JNJ-64417184 / J&J
Trial completion date, Trial primary completion date: A Study of JNJ-64417184, Administered as an Oral Solution, in Healthy Participants (clinicaltrials.gov) - May 27, 2020
P1, N=32, Recruiting, Sponsor: Janssen Research & Development, LLC
N=32 --> 16 Trial completion date: Apr 2020 --> Aug 2020 | Trial primary completion date: Apr 2020 --> Aug 2020
- | Review, Journal: Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference. (Pubmed Central) - May 17, 2020
Other topics included considerations of novel endpoints such as ordinal scales and patient reported outcomes (PRO), and study design issues, and other regulatory considerations for antiviral drug development. The aim of this report is to provide a summary of the presentations given at this meeting.
- | Intelence (etravirine) / J&J, JNJ-64417184 / J&J
Trial completion: A Study to Assess the Effects of Itraconazole and Etravirine on JNJ-64417184 in Healthy Adult Participants (clinicaltrials.gov) - Mar 26, 2020
P1, N=32, Completed, Sponsor: Janssen Research & Development, LLC
The aim of this report is to provide a summary of the presentations given at this meeting. Active, not recruiting --> Completed
- | Intelence (etravirine) / J&J, JNJ-64417184 / J&J
Enrollment closed: A Study to Assess the Effects of Itraconazole and Etravirine on JNJ-64417184 in Healthy Adult Participants (clinicaltrials.gov) - Mar 19, 2020
P1, N=32, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | JNJ-64417184 / J&J
Enrollment open: A Study of JNJ-64417184, Administered as an Oral Solution, in Healthy Participants (clinicaltrials.gov) - Feb 27, 2020
P1, N=32, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | JNJ-64417184 / J&J
New P1 trial: A Study of JNJ-64417184, Administered as an Oral Solution, in Healthy Participants (clinicaltrials.gov) - Feb 6, 2020
P1, N=32, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- ||| JNJ-64417184 / J&J
Trial completion: A First-In-Human Study of Orally Administered JNJ-64417184 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses, and the Antiviral Activity of Multiple Doses in a Respiratory Syncytial Virus (RSV) Challenge Study in Healthy Participants (clinicaltrials.gov) - Jan 29, 2020
P1, N=130, Completed, Sponsor: Janssen BioPharma, Inc.
Not yet recruiting --> Recruiting Recruiting --> Completed
- | Intelence (etravirine) / J&J, JNJ-64417184 / J&J
Enrollment open: A Study to Assess the Effects of Itraconazole and Etravirine on JNJ-64417184 in Healthy Adult Participants (clinicaltrials.gov) - Jan 27, 2020
P1, N=32, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed Not yet recruiting --> Recruiting
- | JNJ-64417184 / J&J
Trial completion: A Study in Healthy Volunteers to Assess the Effect of Different Types of Food on a Single-dose of JNJ-64417184 Administered as Tablets (clinicaltrials.gov) - Jan 27, 2020
P1, N=20, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Recruiting --> Completed
- | rilematovir (JNJ-53718678) / J&J, JNJ-64417184 / J&J
Trial completion: A Study to Assess Interaction Between JNJ-64417184 and JNJ-53718678 After Single and Multiple Dosing in Healthy Participants (clinicaltrials.gov) - Jan 27, 2020
P1, N=16, Completed, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed Recruiting --> Completed
- | Intelence (etravirine) / J&J, JNJ-64417184 / J&J
New P1 trial: A Study to Assess the Effects of Itraconazole and Etravirine on JNJ-64417184 in Healthy Adult Participants (clinicaltrials.gov) - Dec 22, 2019
P1, N=32, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- | JNJ-64417184 / J&J
Enrollment open: A Study in Healthy Volunteers to Assess the Effect of Different Types of Food on a Single-dose of JNJ-64417184 Administered as Tablets (clinicaltrials.gov) - Nov 18, 2019
P1, N=20, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed Not yet recruiting --> Recruiting
- | JNJ-64417184 / J&J
New P1 trial: A Study in Healthy Volunteers to Assess the Effect of Different Types of Food on a Single-dose of JNJ-64417184 Administered as Tablets (clinicaltrials.gov) - Oct 9, 2019
P1, N=20, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- | rilematovir (JNJ-53718678) / J&J, JNJ-64417184 / J&J
Enrollment open: A Study to Assess Interaction Between JNJ-64417184 and JNJ-53718678 After Single and Multiple Dosing in Healthy Participants (clinicaltrials.gov) - Oct 6, 2019
P1, N=16, Recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | JNJ-64417184 / J&J
Trial completion: A Study to Assess the Relative Oral Bioavailability and Food Effect of Single-dose of JNJ-64417184 in Healthy Participants (clinicaltrials.gov) - Sep 23, 2019
P1, N=18, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Recruiting --> Completed
- | rilematovir (JNJ-53718678) / J&J, JNJ-64417184 / J&J
New P1 trial: A Study to Assess Interaction Between JNJ-64417184 and JNJ-53718678 After Single and Multiple Dosing in Healthy Participants (clinicaltrials.gov) - Sep 15, 2019
P1, N=16, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- | JNJ-64417184 / J&J
Trial completion date, Trial primary completion date: A First-In-Human Study of Orally Administered JNJ-64417184 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses, and the Antiviral Activity of Multiple Doses in a Respiratory Syncytial Virus (RSV) Challenge Study in Healthy Participants (clinicaltrials.gov) - Aug 7, 2019
P1, N=122, Recruiting, Sponsor: Janssen BioPharma, Inc.
Recruiting --> Completed Trial completion date: Jun 2019 --> Dec 2019 | Trial primary completion date: Jun 2019 --> Dec 2019
- | JNJ-64417184 / J&J
Enrollment open: A Study to Assess the Relative Oral Bioavailability and Food Effect of Single-dose of JNJ-64417184 in Healthy Participants (clinicaltrials.gov) - Jun 12, 2019
P1, N=18, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Jun 2019 --> Dec 2019 | Trial primary completion date: Jun 2019 --> Dec 2019 Not yet recruiting --> Recruiting
- | JNJ-64417184 / J&J
New P1 trial: A Study to Assess the Relative Oral Bioavailability and Food Effect of Single-dose of JNJ-64417184 in Healthy Participants (clinicaltrials.gov) - May 15, 2019
P1, N=18, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- | JNJ-64417184 / J&J
Trial completion date, Trial primary completion date: A First-In-Human Study of Orally Administered JNJ-64417184 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses, and the Antiviral Activity of Multiple Doses in a Respiratory Syncytial Virus (RSV) Challenge Study in Healthy Participants (clinicaltrials.gov) - Oct 18, 2018
P1, N=122, Recruiting, Sponsor: Alios Biopharma Inc.
Not yet recruiting --> Recruiting Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2018 --> Jun 2019
- ||| JNJ-64417184 / J&J
Enrollment open: A First-In-Human Study of Orally Administered JNJ-64417184 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses, and the Antiviral Activity of Multiple Doses in a Respiratory Syncytial Virus (RSV) Challenge Study in Healthy Participants (clinicaltrials.gov) - Jun 12, 2018
P1, N=122, Recruiting, Sponsor: Alios Biopharma Inc.
Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2018 --> Jun 2019 Not yet recruiting --> Recruiting
- || JNJ-64417184 / J&J
Trial completion date, Trial primary completion date: A First-In-Human Study of Orally Administered JNJ-64417184 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses, and the Antiviral Activity of Multiple Doses in a Respiratory Syncytial Virus (RSV) Challenge Study in Healthy Participants (clinicaltrials.gov) - Mar 29, 2018
P1, N=122, Not yet recruiting, Sponsor: Alios Biopharma Inc.
Not yet recruiting --> Recruiting Trial completion date: Aug 2018 --> Dec 2018 | Trial primary completion date: Aug 2018 --> Dec 2018
- ||| JNJ-64417184 / J&J
New P1 trial: A First-In-Human Study of Orally Administered JNJ-64417184 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses, and the Antiviral Activity of Multiple Doses in a Respiratory Syncytial Virus (RSV) Challenge Study in Healthy Participants (clinicaltrials.gov) - Jan 17, 2018
P1, N=122, Not yet recruiting, Sponsor: Alios Biopharma Inc.